Edition:
India

Puma Biotechnology Inc (PBYI.OQ)

PBYI.OQ on NASDAQ Stock Exchange Global Select Market

98.20USD
15 Dec 2017
Change (% chg)

$-1.50 (-1.50%)
Prev Close
$99.70
Open
$99.70
Day's High
$101.05
Day's Low
$97.90
Volume
877,995
Avg. Vol
242,321
52-wk High
$136.90
52-wk Low
$28.35

Latest Key Developments (Source: Significant Developments)

Puma Biotechnology Announces Positive Outcome Of European Opposition Proceedings
Monday, 11 Dec 2017 

Dec 11 (Reuters) - Puma Biotechnology Inc ::PUMA BIOTECHNOLOGY ANNOUNCES POSITIVE OUTCOME OF EUROPEAN OPPOSITION PROCEEDINGS.PUMA BIOTECHNOLOGY - EUROPEAN PATENT OFFICE HAS UPHELD CLAIMS IN PUMA'S LICENSED EUROPEAN PATENT, EP 2416774, WHICH WERE BEING OPPOSED BY HEXAL AG.  Full Article

PUMA BIOTECHNOLOGY, SPECIALISED THERAPEUTICS ASIA AGREE TO COMMERCIALIZE NERLYNX IN SOUTH EAST ASIA
Wednesday, 22 Nov 2017 

Nov 22 (Reuters) - Puma Biotechnology Inc ::PUMA BIOTECHNOLOGY AND SPECIALISED THERAPEUTICS ASIA ENTER INTO EXCLUSIVE LICENSING AGREEMENT TO COMMERCIALIZE NERLYNX® (NERATINIB) IN AUSTRALIA, NEW ZEALAND AND SOUTH EAST ASIA.PUMA BIOTECHNOLOGY INC - ‍PUMA WILL RECEIVE UPFRONT AND MILESTONE PAYMENTS OF UP TO $4.5 MILLION THROUGHOUT TERM OF THE AGREEMENT​.PUMA BIOTECHNOLOGY-SPECIALISED THERAPEUTICS RESPONSIBLE FOR SEEKING REGULATORY APPROVALS, FOR COMMERCIALIZING NERLYNX IN SOUTH EAST ASIAN COUNTRIES.PUMA BIOTECHNOLOGY INC - ‍EXPECT TO HAVE REGULATORY APPROVAL FOR NERLYNX IN AUSTRALIA BY Q2 OF 2019​.  Full Article

Puma Biotechnology reports Q3 adj. loss per share $1.36
Friday, 10 Nov 2017 

Nov 9 (Reuters) - Puma Biotechnology Inc :Puma Biotechnology reports third quarter 2017 financial results.Q3 adjusted non-GAAP loss per share $1.36.Q3 earnings per share view $-2.58 -- Thomson Reuters I/B/E/S.Q3 loss per share $2.07.  Full Article

Puma Biotechnology secures $100 mln term loan from Silicon Valley Bank and Oxford Finance
Friday, 3 Nov 2017 

Nov 2 (Reuters) - Puma Biotechnology Inc :Puma Biotechnology secures $100 million term loan from Silicon Valley Bank and Oxford Finance.Puma Biotechnology - ‍proceeds from financing will be used to continue to support Nerlynx commercial activities, ongoing research with neratinib ​.  Full Article

Puma Biotechnology's marketing authorization application for neratinib validated by EMA
Tuesday, 23 Aug 2016 

Puma Biotechnology Inc :Marketing authorization application for neratinib has been validated by European Medicines Agency.  Full Article

Puma Biotechnology Q2 adjusted non-gaap loss per share $1.17
Wednesday, 10 Aug 2016 

Puma Biotechnology Inc : Q2 adjusted non-gaap loss per share $1.17 . Q2 loss per share $2.05 . Puma biotechnology reports second quarter 2016 financial results . Q2 earnings per share view $-2.18 -- Thomson Reuters I/B/E/S .Puma biotechnology inc says look forward to continuing our development of neratinib in second half of 2016 and beyond.  Full Article

Puma Biotechnology announces 5-year data on breast cancer
Friday, 22 Jul 2016 

Puma Biotechnology Inc [PBYI.N] : "look forward to obtaining full 5-year dfs data, which we anticipate will be available in 2017" .Puma biotechnology announces interim 5-year disease free survival data from phase iii trial of pb272 (neratinib) in extended adjuvant her2-positive early stage breast cancer (extenet trial).  Full Article

Puma Biotech applies for marketing approval for breast cancer drug
Friday, 22 Jul 2016 

Puma Biotechnology Inc :Submits NDA for PB272 (neratinib) to U.S. FDA for extended adjuvant treatment of HER2-positive early stage breast cancer.  Full Article

Paulson & Co ups share stake in Puma Biotechnology Inc by 52.8 pct to 70,300 shares - Sec Filing
Tuesday, 17 May 2016 

Paulson & Co: Paulson & Co ups share stake in Puma Biotechnology Inc by 52.8 pct to 70,300 shares - Sec Filing .Change in holdings are as of March 31, 2016 and compared with the previous quarter ended as of December 31, 2015.  Full Article

Puma Biotechnology reports Q1 loss per share $2.19
Wednesday, 11 May 2016 

Puma Biotechnology Inc : Puma biotechnology reports first quarter 2016 financial results . Q1 adjusted non-gaap loss per share $1.28 . Q1 earnings per share view $-1.99 -- Thomson Reuters I/B/E/S .Q1 loss per share $2.19.  Full Article

BRIEF-Daiichi Sankyo And Puma Biotechnology To Collaborate With Major Cancer Center In HER2-Mutated Cancer

* DAIICHI SANKYO AND PUMA BIOTECHNOLOGY ANNOUNCE RESEARCH COLLABORATION WITH MAJOR CANCER CENTER IN HER2-MUTATED CANCER Source text for Eikon: Further company coverage: